209 related articles for article (PubMed ID: 34203430)
1. Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer.
Nakamura Y
Cells; 2021 Jun; 10(7):. PubMed ID: 34203430
[TBL] [Abstract][Full Text] [Related]
2. The FGF2 aptamer inhibits the growth of FGF2-FGFR pathway driven lung cancer cells.
Hamamoto J; Yasuda H; Nonaka Y; Fujiwara M; Nakamura Y; Soejima K; Betsuyaku T
Biochem Biophys Res Commun; 2018 Sep; 503(3):1330-1334. PubMed ID: 30005872
[TBL] [Abstract][Full Text] [Related]
3. Anti-Angiogenic and Anti-Scarring Dual Action of an Anti-Fibroblast Growth Factor 2 Aptamer in Animal Models of Retinal Disease.
Matsuda Y; Nonaka Y; Futakawa S; Imai H; Akita K; Nishihata T; Fujiwara M; Ali Y; Bhisitkul RB; Nakamura Y
Mol Ther Nucleic Acids; 2019 Sep; 17():819-828. PubMed ID: 31454678
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology.
Cao J; Zhang F; Xiong W
Int J Nanomedicine; 2023; 18():4421-4430. PubMed ID: 37551274
[TBL] [Abstract][Full Text] [Related]
5. Dual Therapeutic Action of a Neutralizing Anti-FGF2 Aptamer in Bone Disease and Bone Cancer Pain.
Jin L; Nonaka Y; Miyakawa S; Fujiwara M; Nakamura Y
Mol Ther; 2016 Nov; 24(11):1974-1986. PubMed ID: 27506449
[TBL] [Abstract][Full Text] [Related]
6. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
Ng EW; Shima DT; Calias P; Cunningham ET; Guyer DR; Adamis AP
Nat Rev Drug Discov; 2006 Feb; 5(2):123-32. PubMed ID: 16518379
[TBL] [Abstract][Full Text] [Related]
7. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
Waisbourd M; Loewenstein A; Goldstein M; Leibovitch I
Drugs Aging; 2007; 24(8):643-62. PubMed ID: 17702534
[TBL] [Abstract][Full Text] [Related]
8. Pegaptanib for the treatment of age-related macular degeneration.
Zhou B; Wang B
Exp Eye Res; 2006 Sep; 83(3):615-9. PubMed ID: 16678158
[TBL] [Abstract][Full Text] [Related]
9. An RNA aptamer restores defective bone growth in FGFR3-related skeletal dysplasia in mice.
Kimura T; Bosakova M; Nonaka Y; Hruba E; Yasuda K; Futakawa S; Kubota T; Fafilek B; Gregor T; Abraham SP; Gomolkova R; Belaskova S; Pesl M; Csukasi F; Duran I; Fujiwara M; Kavkova M; Zikmund T; Kaiser J; Buchtova M; Krakow D; Nakamura Y; Ozono K; Krejci P
Sci Transl Med; 2021 May; 13(592):. PubMed ID: 33952673
[TBL] [Abstract][Full Text] [Related]
10. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.
de Oliveira Dias JR; Rodrigues EB; Maia M; Magalhães O; Penha FM; Farah ME
Br J Ophthalmol; 2011 Dec; 95(12):1631-7. PubMed ID: 21546514
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor-2, derived from cancer-associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling.
Suh J; Kim DH; Lee YH; Jang JH; Surh YJ
Mol Carcinog; 2020 Sep; 59(9):1028-1040. PubMed ID: 32557854
[TBL] [Abstract][Full Text] [Related]
12. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
13. Pegaptanib for wet macular degeneration.
Fraunfelder FW
Drugs Today (Barc); 2005 Nov; 41(11):703-9. PubMed ID: 16395411
[TBL] [Abstract][Full Text] [Related]
14. The role of FGF2 in migration and tubulogenesis of endothelial progenitor cells in relation to pro-angiogenic growth factor production.
Litwin M; Radwańska A; Paprocka M; Kieda C; Dobosz T; Witkiewicz W; Baczyńska D
Mol Cell Biochem; 2015 Dec; 410(1-2):131-42. PubMed ID: 26314253
[TBL] [Abstract][Full Text] [Related]
15. Electrical stimulation facilitates the angiogenesis of human umbilical vein endothelial cells through MAPK/ERK signaling pathway by stimulating FGF2 secretion.
Geng K; Wang J; Liu P; Tian X; Liu H; Wang X; Hu C; Yan H
Am J Physiol Cell Physiol; 2019 Aug; 317(2):C277-C286. PubMed ID: 30995109
[TBL] [Abstract][Full Text] [Related]
16. Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts.
Hegab AE; Ozaki M; Kameyama N; Gao J; Kagawa S; Yasuda H; Soejima K; Yin Y; Guzy RD; Nakamura Y; Ornitz DM; Betsuyaku T
J Pathol; 2019 Oct; 249(2):193-205. PubMed ID: 31090071
[TBL] [Abstract][Full Text] [Related]
17. HDGF enhances VEGF‑dependent angiogenesis and FGF‑2 is a VEGF‑independent angiogenic factor in non‑small cell lung cancer.
Eguchi R; Wakabayashi I
Oncol Rep; 2020 Jul; 44(1):14-28. PubMed ID: 32319650
[TBL] [Abstract][Full Text] [Related]
18. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.
Ng EW; Adamis AP
Can J Ophthalmol; 2005 Jun; 40(3):352-68. PubMed ID: 15947805
[TBL] [Abstract][Full Text] [Related]
19. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases.
Ng EW; Adamis AP
Ann N Y Acad Sci; 2006 Oct; 1082():151-71. PubMed ID: 17145936
[TBL] [Abstract][Full Text] [Related]
20. Impact of VEGF-dependent tumour micro-environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice.
Coltrini D; Ronca R; Belleri M; Zardi L; Indraccolo S; Scarlato V; Giavazzi R; Presta M
J Pathol; 2009 Dec; 219(4):455-62. PubMed ID: 19824060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]